Your browser is no longer supported. Please, upgrade your browser.
Dyne Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.28 Insider Own0.10% Shs Outstand49.55M Perf Week4.18%
Market Cap902.17M Forward P/E- EPS next Y-3.06 Insider Trans0.00% Shs Float21.21M Perf Month5.31%
Income-59.40M PEG- EPS next Q-0.60 Inst Own87.90% Short Float8.38% Perf Quarter-39.93%
Sales- P/S- EPS this Y-286.80% Inst Trans54.83% Short Ratio3.84 Perf Half Y-1.30%
Book/sh6.91 P/B2.53 EPS next Y-18.60% ROA- Target Price- Perf Year-
Cash/sh6.68 P/C2.61 EPS next 5Y- ROE- 52W Range13.50 - 32.31 Perf YTD-16.90%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.00% Beta-
Dividend %- Quick Ratio31.80 Sales past 5Y- Gross Margin- 52W Low29.26% ATR0.88
Employees47 Current Ratio31.80 Sales Q/Q- Oper. Margin- RSI (14)57.83 Volatility4.27% 5.98%
OptionableYes Debt/Eq0.00 EPS Q/Q-603.10% Profit Margin- Rel Volume0.42 Prev Close17.53
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume463.19K Price17.45
Recom1.60 SMA209.23% SMA501.13% SMA200-10.71% Volume195,281 Change-0.46%
Oct-12-20Initiated Stifel Buy $29
Oct-12-20Initiated Piper Sandler Overweight $34
Oct-12-20Initiated JP Morgan Overweight $27
Oct-12-20Initiated Jefferies Buy $47
Mar-04-21 07:35AM  
Feb-08-21 07:30AM  
Jan-27-21 01:13AM  
Jan-20-21 08:05PM  
Jan-10-21 03:00PM  
Jan-05-21 07:30AM  
Dec-08-20 10:17AM  
Nov-09-20 07:30AM  
Nov-05-20 07:35AM  
Oct-09-20 03:41PM  
Sep-21-20 04:05PM  
Sep-16-20 07:00PM  
Dec-13-19 03:38PM  
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.